Introduction of novel agents in the treatment of primary CNS lymphoma

Christian Grommes, Lakshmi Nayak, Han W. Tun, Tracy T. Batchelor

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Novel insights into the pathophysiology of primary central nervous system lymphoma (PCNSL) have identified the B-cell receptor and Toll-like receptor pathway as well as immune evasion and suppressed tumor immune microenvironment as a key mechanism in the pathogenesis of PCNSL. Small molecules and novel agents targeting these aberrant pathways have been introduced into clinical trials targeting the recurrent or refractory PCNSL patient population. Agents like the Bruton tyrosine kinase (BTK) inhibitor ibrutinib or immunomodulatory drugs (IMiDs) like pomalidomide and lenalidomide have shown promising high response rates in the salvage setting. Here, we give an overview about the recent, exciting developments in PCNSL and summarize the results of clinical trials using novel agents in the recurrent and refractory salvage setting, which include immune checkpoint inhibitors, IMiDs, as well as BTK, phosphatidylinositol-3 kinase, and mammalian target of rapamycin inhibitors.

Original languageEnglish (US)
Pages (from-to)306-313
Number of pages8
JournalNeuro-oncology
Volume21
Issue number3
DOIs
StatePublished - Jan 1 2019

Keywords

  • BTK
  • IMiD
  • Immune checkpoint inhibition
  • PCNSL
  • Targeted agents

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'Introduction of novel agents in the treatment of primary CNS lymphoma'. Together they form a unique fingerprint.

  • Cite this